In 2021, the team of Professor Li Hongliang has made important progress in the fields of cardiovascular and metabolic diseases.

The research field of Li Hongliang's team covers the fields of cardiovascular disease, metabolic disease, and clinical big data research of new coronary pneumonia.
A series of small molecule lead drugs have been developed by batch of key targets
.
It provides a new important theoretical basis for understanding cardiometabolic diseases, and also provides a series of new ideas and potential targets for the development of new drugs in this field

Development of a new therapeutic drug for cardiometabolic diseases

Cardiometabolic disease has become the number one killer of human death
.
In order to solve the problem of the pathogenesis and clinical treatment of cardiometabolic diseases, Professor Li Hongliang's team has comprehensively applied cutting-edge technologies such as biological big data, disease animal models, and artificial intelligence drug design for more than ten years.

The series of results were published as a cover article in the journal Science Translational Medicine back-to-back on December 15, 2021, and were listed as a highlight research in the special issue of the journal Science published on December 17
.
At the same time, the research team also found for the first time that ML355, a small molecule inhibitor of ALOX12, can effectively improve cardiac ischemia-reperfusion injury in mice, Bama pigs and rhesus monkeys, and significantly improve cardiac function.

Figure 1: A.
IMA-1 inhibits ALOX12 and ACC1 protein interaction structure; Figure B.
IMA-1 treatment of steatohepatitis (red staining area represents the degree of liver fibrosis)

Discover key therapeutic targets for a range of metabolic diseases

Obesity, type 2 diabetes, and NAFLD are the main causes of metabolic syndrome.
In order to better address these health threats, Professor Li Hongliang's team has conducted an in-depth exploration of the pathogenesis of the disease
.
Using advanced technologies such as large-scale systems biology screening analysis, immunofluorescence, and overexpression adenovirus treatment, the research team found that TMBIM1 inhibits adipogenesis by reducing the stability of PPARγ, and is a new factor that effectively inhibits adipogenesis.

Figure 2: Novel mechanism of TMBIM1 regulation of adipogenesis Figure 3: NLK promotes nuclear export of CRTC2 and FOXO1
　　

    Study finds driving risk factors for cardiovascular disease

　　Cardiovascular disease has become the leading cause of increased mortality worldwide
.
In recent years, with the development of society, the improvement of people's living standards and the change of life>

　　Solve the problem of new crown drug use and develop risk assessment tools

　　The new coronavirus is still threatening human health around the world
.
How hormones should be used in the initial treatment of Covid-19 patients has been a controversial issue

　　Figure 5: Boundary of glucocorticoid use in the treatment of new coronary pneumonia

　　It is understood that in 2021, Professor Li Hongliang's team has published a total of 29 research papers in Cell Metab, Sci Transl Med, Circ Res, Hepatology, Trends Mol Med and other international authoritative journals, of which 15 have SCI impact factors higher than 10.
There are 5 articles in 20
.
According to statistics, over the past ten years, the team has published a total of 136 research papers with the People's Hospital as the first unit

　　In terms of subject areas, it has been selected as a highly cited scholar for seven consecutive years
.
On April 22, 2021, the international authoritative academic publisher Elsevier released the 2020 "Highly Cited Chinese Researchers" list, and Professor Li Hongliang was selected into the list of clinical medicine

　　On September 22, 2021, the Global Scholar Database released the "2020 Top 100 High-Value Papers in Cardiovascular Medicine in China" list.
A total of 10 papers from the team of Li Hongliang of Wuhan University were included in the TOP50 list, which is the cardiovascular medicine with the largest number of papers.
research team
.

　　According to reports, the Institute of Model Animals is an important carrier to support the development of disciplines in the medical field of Wuhan University, the improvement of scientific research level and the training of high-level talents, and it is also a high-end scientific research institution that provides leading services for medical research
.
In the past ten years, Professor Li Hongliang's team has unswervingly guided the construction of medical disciplines, promoted the high-quality development of the affiliated hospitals, and supported the discipline construction, scientific research, and personnel training of the People's Hospital and Zhongnan Hospital
.

　　In the past 13 years, the team has served more than 1,000 people in the Department of Cardiology, Oncology, Gastroenterology and other departments of the People's Hospital.
Each department has published more than 700 papers on the platform of the Institute, and applied for and carried out more than 100 national projects
.
According to the "2020 Chinese Hospital/Chinese Medical College Science and Technology Value (STEM)" ranking released in October 2021, the cardiovascular discipline ranking of the People's Hospital has risen to the third highest in history; cardiovascular science and technology output ranks second in the country bit
.
According to the search and analysis of international institutions, the research activity of the global cardiovascular field in 2020, the People's Hospital ranks 4th in the world and 3rd in China
.

　　Professor Li Hongliang's team steadily promotes the construction of a high-level, high-level and high-level scientific research platform in Zhongnan Hospital of Wuhan University
.
In 2021, the scientific research service capabilities of the Medical Science Research Center will continue to improve, and the effect of supporting the development of disciplines will be remarkable
.
In the past five years, the overall number of service people has increased by nearly 5 times.
In 2021, the total number of services will be 290,300.
The center has settled in 183 research groups, and has achieved full coverage of hospital disciplines.
It has trained more than 40,000 scientific researchers.
The coverage ratio of undergraduate and postgraduate students is 100%
.
The average use time of precision experimental instruments on each platform increased by about 289%, of which the annual increase of flow cytometer users was 157.
1%, and the annual increase of automatic slide scanners was 229.
7%
.
In terms of discipline construction, the team has further improved the level of discipline development in the hospital by exploring the support service model for various disciplines in the hospital
.

　　In the new year, the team will be oriented to solve major clinical practical problems, continuously advance to the depth and breadth of scientific research, promote the transformation of scientific and technological achievements into real productivity, promote and lead the innovation and development of medical science and technology, and contribute to the development of health care
.